Ex­clu­sive: Gen­mab's CEO touts M&A po­ten­tial as it inks first part­ner­ship out­side can­cer

Slow­ly and steadi­ly, the Dan­ish an­ti­body spe­cial­ist Gen­mab has grown in­to a $27 bil­lion mar­ket cap pow­er­house dri­ven by can­cer re­search.

Now, Gen­mab is mak­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER